Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.
DTC - Differentiated Thyroid Cancer
DRUG: Anlotinib hydrochloride
The changes in glucose metabolism, Evaluated by maximum standard uptake value (SUVmax), up to 24 months
Time to response (TTR), up to 24 months|PFS, up to 24 months
The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.